The cognitive tier, mapped.

BDNF is the primary driver of neuroplasticity. Synaptic density, learning rate, and memory consolidation all depend on it. The peptides and compounds that modulate BDNF and its receptor TrkB are the most evidence-grounded tools in the cognitive optimization tier.

I. BDNF and neuroplasticity.

BDNF (brain-derived neurotrophic factor) is a member of the neurotrophin family. It binds TrkB (tropomyosin receptor kinase B) and activates downstream signaling cascades, specifically MAPK/ERK and PI3K/Akt, governing neuronal survival, synaptic plasticity, and long-term potentiation. verified

LTP (long-term potentiation) is the synaptic mechanism of memory formation. BDNF is required for late-phase LTP: the consolidation window where short-term synaptic change becomes structural, durable memory. Without adequate BDNF signaling, the late phase does not complete. verified [I]

BDNF declines with age, chronic stress, sleep deprivation, sedentary behavior, and elevated inflammatory load. It increases robustly with aerobic exercise, caloric restriction, ketosis, and sustained cognitive challenge. The modifiable drivers are substantial. verified

Serum BDNF is measurable and serves as a useful proxy for CNS BDNF trends, but it is not a precise absolute measure. Brain BDNF and peripheral BDNF are related, not identical. Use serum BDNF for trend monitoring across a protocol. Do not interpret a single value in isolation. clinical interpretation - inferred

II. Semax and the BDNF-upregulation mechanism.

As detailed in Note XI: Semax is an ACTH(4-10) heptapeptide analog that upregulates BDNF and TrkB expression in the prefrontal cortex and hippocampus. It does not mimic BDNF. It drives the upstream transcriptional machinery that produces BDNF. The distinction is clinically relevant: Semax amplifies the brain's own BDNF synthesis rather than supplying an exogenous ligand. verified

Dolotov OV et al., published in J Neurochem in 2006, demonstrated dose-dependent BDNF upregulation in rodent hippocampus following Semax administration. verified [II]

Clinical effect profile: enhanced focus, working memory, and verbal fluency. Effects are most pronounced in cognitively stressed states: sleep deprivation, high-demand periods, and acute cognitive load. The compound's utility scales with the degree of cognitive stress present, which makes it particularly well-suited to operators running extended high-demand schedules. clinical practice - inferred

Paired with Selank (anxiolytic): the Semax-Selank combination addresses both BDNF-mediated cognitive enhancement and GABAergic anxiety reduction. These are complementary mechanisms operating at different receptor systems. Neither substitutes for the other. The pairing is rational precisely because they do not overlap. verified - mechanistic basis

III. Dihexa and the HGF/c-Met pathway.

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic peptide derived from angiotensin IV. It acts as a potent positive modulator of the HGF/c-Met signaling pathway. HGF (hepatocyte growth factor) activates c-Met, a tyrosine kinase receptor, which drives synaptogenesis: the formation of new synaptic connections between neurons. verified

McCoy AT et al., published in J Pharmacol Exp Ther in 2013, evaluated metabolically stabilized angiotensin IV analogs including Dihexa in rodent models of neurodegeneration. Procognitive effects were demonstrated at potency levels described as significantly exceeding BDNF itself on a molar basis. verified [III]

Human data on Dihexa remains limited. The compound is in early human trials for Alzheimer's disease. The preclinical signal is among the strongest in the nootropic peptide class. Operators considering Dihexa should understand that the evidence tier is animal-model-dominant with emerging human trial data. That is the honest framing. verified - trial status

IV. NSI-189 and hippocampal neurogenesis.

NSI-189 (benzylpiperazine aminopyridine) is a small molecule, not a peptide, that stimulates neurogenesis in the hippocampus via a mechanism distinct from BDNF upregulation. The precise mechanism remains under investigation. What is documented is hippocampal volume increase and neurogenic activity in preclinical models, with cognitive signals in human trials. verified - trial data

The Johe et al. Phase II trial in major depressive disorder evaluated NSI-189 at 40 mg/day. Cognitive secondary outcomes, including digit span and Rey AVLT scores, showed the strongest positive signals in the dataset. The compound did not meet its primary endpoint for depression. verified

V. Cerebrolysin and neuroprotection.

Cerebrolysin is a mixture of neuropeptides and amino acids derived from purified porcine brain proteins. It contains peptide fragments with BDNF-like, NGF-like, and CNTF-like activity. It is not a single compound. It is a standardized biological mixture with a defined neuropeptide fraction. verified

Guekht A et al., published in Stroke in 2017, reported a Phase III trial demonstrating improved neurological outcomes versus placebo in acute ischemic stroke. verified [IV] The compound has been used in European and Asian neurological medicine for decades. The evidence base is strongest for acute neurological injury (stroke, TBI) and Alzheimer's disease. Off-label use for cognitive optimization is clinically reasonable given the mechanism and the safety profile accumulated over decades of use.

Dosing: 5 to 30 mL IV or IM. Course protocols: 5 to 20 consecutive days. Lower doses (5 mL/day) for optimization contexts. Higher doses (10 to 30 mL/day) for neurological injury protocols. Dosing selection should follow the clinical objective. clinical practice - inferred from literature ranges

VI. The cognitive stack framework.

Tier 1 (foundational, non-negotiable): sleep architecture (BDNF is synthesized during sleep; the deficit here cannot be supplemented away), aerobic exercise (the single most robust BDNF stimulus in the literature verified [V]), protein adequacy (neurotransmitter precursor availability), and insulin sensitivity (insulin resistance impairs BDNF signaling at the receptor level).

Tier 2 (evidence-grounded additions): Semax (BDNF upregulation, TrkB expression), Selank (anxiolytic complement, GABAergic modulation), and NAD+ precursors (sirtuin-mediated neuroprotection, mitochondrial function in neurons).

Tier 3 (advanced, informed patient): Dihexa (synaptogenesis via HGF/c-Met), NSI-189 (hippocampal neurogenesis, mixed human evidence), Cerebrolysin (neuroprotective peptide complex, strongest evidence in injury and neurodegeneration contexts).

The stack is not additive in a linear sense. BDNF upregulation without adequate sleep to consolidate synaptic changes is partially wasted. The substrate conditions in Tier 1 must be established before Tier 3 compounds can fully express their mechanism. Prescribing Dihexa to a patient with disordered sleep and insulin resistance is not a rational protocol. It is optimizing the wrong variable. clinical reasoning - inferred

THE PIVOTAL PROTOCOL is an intelligence and education layer, not a prescriber. The mechanisms described here are derived from the cited literature and from Pivotal's own protocol design history. Every clinical decision belongs to a licensed physician with full knowledge of the case. Begin a conversation. Do not begin self-administration from a website.